Table 1 |
||||||
|
Clinical characteristics of subjects in the follicular and late luteal phase |
||||||
| Control group (n = 28) |
PMS group (n = 23) |
PMDD group (n = 11) |
||||
|
|
||||||
| Follicular |
Luteal |
Follicular |
Luteal |
Follicular |
Luteal |
|
|
|
||||||
| Estrone (ng/ml Cr) |
10.7 ± 1.0 |
19.4 ± 2.2** |
10.9 ± 1.4 |
19.3 ± 2.5** |
11.3 ± 2.8 |
21.7 ± 3.5* |
| Pregnanediol-3-glucuronide (μg/ml Cr) |
0.4 ± 0.04 |
2.1 ± 0.19** |
0.3 ± 0.04 |
2.2 ± 0.3** |
0.8 ± 0.4 |
2.1 ± 0.4 |
| Weight (kg) |
54.7 ± 1.2 |
55.0 ± 1.3 |
55.9 ± 1.6 |
56.0 ± 1.6 |
51.8 ± 2.4 |
52.6 ± 2.4 |
| Body Mass Index (kg/m2) |
21.9 ± 0.5 |
22.0 ± 0.5 |
21.1 ± 0.5 |
21.2 ± 0.5 |
20.5 ± 0.9 |
20.8 ± 0.9 |
|
Cr: creatinine Values are means ± SE. **p < 0.01; *p < 0.05 (follicular phase vs. late luteal phase) | ||||||
Matsumoto et al. BioPsychoSocial Medicine 2007 1:24 doi:10.1186/1751-0759-1-24 |
||||||
